Clofarabine

Name: Clofarabine
Brand: Selleck Chemicals
SKU: S1218
Rating: 5 (12 reviews)

For research use only.

Catalog No.S1218 Synonyms: Clolar

12 publications

CAS No. 123318-82-1

Clofarabine (Clolar) inhibits the enzymatic activities of ribonucleotide reductase (RNR) (IC50 = 65 nM) and DNA polymerase. Clofarabine induces autophagy and apoptosis.

Selleck's Clofarabine has been cited by 12 publications

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

EMBO J, 2018, 37(14)

PubMed: 29875130 ( click the link to review the publication )

Oncogene, 2018, 37(16):2181-2196

PubMed: 29382926 ( click the link to review the publication )

Exp Hematol, 2018, 67:49-59

PubMed: 30102945 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432.CCR-17-0263

PubMed: 28442502 ( click the link to review the publication )

Oncotarget, 2017, 8(50):87016-87032

PubMed: 29152060 ( click the link to review the publication )

Cancer Chemoth Pharm, 2015, 10.1007/s00280-015-2713-z

PubMed: 25724157 ( click the link to review the publication )

2 Customer Reviews

Immunoblot analysis of cell lysates of NCI-H929 cells treated with CLO (5 μM, 3-48 h) GAPDH served as the loading control for each membrane, and data are representative of at least two independent experiments

Clin Cancer Res, 2017, 23(17):5225-5237. Clofarabine purchased from Selleck.

Population-based pharmacokinetic modeling of plasma pharmacokinetic study and cerebral microdialysis study. Representative individual plasma and/or tumor ECF concentration-time profile of unbound clofarabine from plasma pharmacokinetic study (a) and cerebral microdialysis study (b) (open circles and triangles represent observed clofarabine unbound plasma and tumor ECF concentrations, respectively; Dotted and solid lines represent model-predicted individual unbound plasma and tumor ECF concentrations, respectively). Box plot comparison of individual volume of peripheral compartment (c) and systemic clearance (d) between plasma pharmacokinetic study (45 mg/kg clofarabine) and cerebral microdialysis study (30 mg/kg clofarabine).

Cancer Chemoth Pharm, 2015, 75:897-906.. Clofarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Clofarabine (Clolar) inhibits the enzymatic activities of ribonucleotide reductase (RNR) (IC50 = 65 nM) and DNA polymerase. Clofarabine induces autophagy and apoptosis.

Targets

Ribonucleotide reductase ^[1]
(Cell-free assay)

65 nM

In vitro

Clofarabine is efficiently transported into cells via two facilitative or equilibrative nucleoside transporters, hENT1 and hENT2, and a concentrative nucleoside transporter, hCNT253. Clofarabine is phosphorylated in a stepwise manner by cytosolic kinases to the nucleotide analogues clofarabine 5′-mono-, di- and triphosphate following entry into cells, with Clofarabine triphosphate being the active form. Clofarabine 5′-mono-, di- and triphosphate are not substrates for nucleoside transporters and must be enzymatically converted by 5′-nucleotidase back to their dephosphorylated nucleoside form for transport out of the cell. Clofarabine triphosphate is a potent inhibitor of ribonucleotide reductase (IC50 = 65 nM), presumably by binding to the allosteric site on the regulatory subunit. Clofarabine has also been shown to act directly on mitochondria by altering the transmembrane potential with release of cytochrome c, apoptotic-inducing factor (AIF), apoptosis protease-activating factor 1 (APAF1) and caspase 9 into the cytosol. Clofarabine demonstrates strong in vitro growth inhibition and cytotoxic activity (IC50 values = 0.028–0.29 μM) in a wide variety of leukaemia and solid tumour cell lines. Clofarabine has been shown to increase the activity of dCK in HL60 cells, and increases the formation of the mono-, di-, and triphosphates of ara-C in K562 cells36. ^[1] Clofarabine (10 μM) inhibits the repair initiated by 4-hydroperoxycyclophosphamide (4-HC), with inhibition peaking at the intracellular concentrations of 5 μM in chronic lymphocytic leukemia (CLL) lymphocytes. Clofarabine (10 μM) combined with 4-hydroperoxycyclophosphamide (4-HC) produces more than additive apoptotic cell death than the sum of each alone. ^[2] Clofarabine (1 μM) combined with ara-C (10 μM) results in a biochemical modulation of ara-CTP and synergistic cell kill in K562 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
K562 cell	MkLuR5l1d3SxeHnjbZR6KGG\|c3H5			NIDDSpREd22yb4Xu[EB4[XNidHXzeIVlKG[xcjDjfZRwfG:6aXPpeJkh[WejaX7zeEBMPTZ{IHPlcIwhdGmwZYOsJGlEPTB;MD6wNFMh\|ryP	Mn3RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|MkW1Okc,OTd\|MkW1Olww[T5?
HEp-2 cell	M2PnUWN6fG:2b4jpZ4l1gSCjc4PhfS=>			NV:x[XNPS2:vcH;1coQhf2G\|IITld5Rm\CCob4KgZ5l1d3SxeHnjbZR6KGGpYXnud5QhUEWyLUKgZ4VtdCCuaX7ld{whUUN3ME2wMlAyOiEQvF2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzN{NUW2K\|4yPzN{NUW2QE9iRg>?
CCRF-CEM cell lines	NXLLellNS3m2b4TvfIlkcXS7IHHzd4F6			Mnv3R49ueG:3bnSge4F{KHSnc4Tl[EBnd3JiY4n0c5RwgGmlaYT5JIFo[Wmwc4SgR2NTTi2FRV2gZ4VtdCCuaX7ld{whUUN3ME2wMlA2KM7:TR?=	NF\3TII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OyOVU3Lz5zN{OyOVU3RC:jPh?=
L1210 cell	M{HxXWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MV;Dc41xd3WwZDD3ZZMhfGW\|dHXkJIZweiCleYTveI95cWOrdImgZYdicW6\|dDDMNVIyOCClZXzsJIxqdmW\|LDDJR\|UxRTJwMzFOwG0>	NYjEZ4dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezNlU2Pid-MUezNlU2PjxxYU6=
NCI-H23	M3nFemN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFPEWXE2KGSjeYO=	MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGGodHXyJFUh\GG7czDifUBUWkJiYYPzZZktKEeLNUC9NE4xPM7:TR?=	M2rrdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUK5NFA1Lz5zOUmyPVAxPDxxYU6=
PC3	MkXCR5l1d3SxeHnjbZR6KGG\|c3H5		MlH3OUBl[Xm\|	MnzIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO\|YYmsJGdKPTB;MD6wOlPPxE1?	NU[xW2NyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NlkxODRpPkG5PVI6ODB2PD;hQi=>
BT549	MYnDfZRwfG:6aXPpeJkh[XO\|YYm=		NYjzPFFyPSCmYYnz	MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCWFU1QSClZXzsd{Bi\nSncjC1JIRigXNiYomgV3JDKGG\|c3H5MEBIUTVyPUCuNFY2\|ryP	MlGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MkmwNFQoRjF7OUK5NFA1RC:jPh?=
HCT15	MlfkR5l1d3SxeHnjbZR6KGG\|c3H5		M33FXlUh\GG7cx?=	NYj4cnN6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjF6zszN	MoHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MkmwNFQoRjF7OUK5NFA1RC:jPh?=
NCI-H23	MW\DfZRwe3SjdHnjJIF{e2G7		NGX6R3A2KGSjeYO=	MUnDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOyClZXzsd{Bi\nSncjC1JIRigXNiYomgV3JDKGG\|c3H5MEBIUTVyPUCuNFTPxE1?	M4nkeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
MT4	NUfwUJpES3m2b4P0ZZRq[yCjc4PhfS=>		NVPFS\|VyPSCmYYnz	NEPtZYFEgXSxc4TheIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO\|YYmsJGdKPTB;MD6wOVHPxE1?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
PC3	MnrQR5l1d3O2YYTpZ{Bie3OjeR?=		MnX4OUBl[Xm\|	MlnnR5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB3IHThfZMh[nliU2LCJIF{e2G7LDDHTVUxRTBwME[z{txO	NHjMcW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
BT549	NX;D[W5NS3m2b4P0ZZRq[yCjc4PhfS=>		NUe4TGc3PSCmYYnz	NXPnV3pSS3m2b4P0ZZRq[yCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJGJVPTR7IHPlcIx{KGGodHXyJFUh\GG7czDifUBUWkJiYYPzZZktKEeLNUC9NE4xPjYQvF2=	MlnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
A549	MnrxR5l1d3O2YYTpZ{Bie3OjeR?=		Ml3aOUBl[Xm\|	MUnDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB3IHThfZMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMEi2{txO	MnfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
HCT116	NVf1UHJwS3m2b4P0ZZRq[yCjc4PhfS=>		NIfFUpU2KGSjeYO=	MWLDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO\|YYmsJGdKPTB;MD6xNFbPxE1?	MoTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
DU145	Mn3jR5l1d3O2YYTpZ{Bie3OjeR?=		MVS1JIRigXN?	NHjTeGhEgXSxc4TheIlkKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[W[2ZYKgOUBl[Xm\|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlEzPc7:TR?=	MmSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
HCT15	NX3GbnFXS3m2b4P0ZZRq[yCjc4PhfS=>		M{DH[FUh\GG7cx?=	MnjDR5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFE2KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO\|YYmsJGdKPTB;MD6xPO69VQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
Hs578	M2rlN2N6fG:\|dHH0bYMh[XO\|YYm=		MoXROUBl[Xm\|	Mn7pR5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjzOVc5KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO\|YYmsJGdKPTB;MT6yOFHPxE1?	NHT0dZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
HL60	MmDqR5l1d3O2YYTpZ{Bie3OjeR?=		NHvtU3Q1QCCqcoO=	MkXWR5l1d3O2YYTpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkJOwG0>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{MEW3Nkc,OjN6MkC1O\|I9N2F-
A549	M1SweGN6fG:\|dHH0bYMh[XO\|YYm=		MV60PEBpenN?	MWLDfZRwe3SjdHnjJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTkQvF2=	NHzYR5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyNFU4Oid-MkO4NlA2PzJ:L3G+
U373-MAGI	MUTGeY5kfGmxbjDhd5NigQ>?	NHfQW2c2OCCwTR?=	NYjJN2xQOiCqcoO=	NHjsfFNRd3SnboTpZZRqd25ib3[gOU1CgmFvQz3pcoR2[2WmIHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IG\TWk1IKHC\|ZYXkc5R6eGWmIFjJWk0yKE6OND2zJIlv\mWldHXkJIlvKGi3bXHuJHU{PzNvTVHHTUBk\WyuczDhd5Nme3OnZDDhd{A2NUG8YT3DJGVEPTBiYYSgOVAhdk1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSB3LVH6ZU1EKGGmZHn0bY9vKG[xcjCyJIhzeyCjbnSgd5Vje2WzdXXueEB3cXKjbDDpcoZm[3Srb36gcYVie3VuIFXDOVA:OzBwNN88US=>	NEnqeWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|I3OCd-MkexNVczPjB:L3G+
U373-MAGI	NXj6OmczSW62aY\pdoFtKGG\|c3H5	NUnHeIlsPTBibl2=	M322XVQhcHK\|	NH7L[FJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBXW1ZvRzDwd4V2\G:2eYDl[EBJUVZvMTDOUFQuOyCrbn\lZ5Rm\CCrbjDoeY1idiCXM{ezMW1CT0liY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJJZqemGuIHnu[oVkfGm4aYT5JIF1KDVyIH7NJIlv[3WkYYTl[EBnd3JiNDDodpMheHKrb4KgeI8hfmm{YXygbY5n\WO2aX;uJI1m[XO3cnXkJIF1KDd{IHjyd{Bxd3O2IHnu[oVkfGmxbjDifUBndG:5IHP5eI9u\XS{aXOgZY5idHm\|aYO=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI	NGjtPWdHfW6ldHnvckBie3OjeR?=	MYSyNFAhdk1?	MUW2JIhzew>?	MkDDVoVlfWO2aX;uJIlvKGSJVGCgcIV3\WxiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG2IEKwNEBvVSCjZoTldkA3KGi{czDifUBNSy2PUz;NV{BidmGueYPpdy=>	M4DR[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=
U373-MAGI	NYHa[4d3TnWwY4Tpc44h[XO\|YYm=	M3i0flIxOCCwTR?=	NV\IWVlMPiCqcoO=	M3e2bHJm\HWldHnvckBqdiCmQ2TQJIxmfmWuIHnuJIh2dWGwIGWzO\|MuVUGJSTDj[YxteyCjdDCyNFAhdk1iYX\0[ZIhPiCqcoOgZpkhVENvTWOvUXMh[W6jbInzbZM>	M4jaeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=
U373-MAGI	MljiSpVv[3Srb36gZZN{[Xl?	NHnnO48zODBibl2=	MkTCOkBpenN?	NV3U[mlKWmWmdXP0bY9vKGmwIHTBWHAhdGW4ZXygbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy\|IHH0JFIxOCCwTTDh[pRmeiB4IHjyd{BjgSCOQz3NV{9OWyCjbnHsfZNqew>?	Mme3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI	NXn5R4NTTnWwY4Tpc44h[XO\|YYm=	NGLteVY2OCCwTR?=	MYOyJIhzew>?	NFTrU2VT\WS3Y4Tpc44hcW5iZFPUVEBt\X[nbDDpckBpfW2jbjDVN\|c{NU2DR1mgZ4VtdHNiYYSgOVAhdk1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSB3LXH6ZU1EKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JGxENU2VL13TJIFv[Wy7c3nz	NUPScVltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
U373-MAGI	MnzTSpVv[3Srb36gZZN{[Xl?	MX2yNFAhdk1?	NImwUIEzKGi{cx?=	NUP0SJloWmWmdXP0bY9vKGmwIHTDWHAhdGW4ZXygbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy\|IHH0JFIxOCCwTTDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IEWtZZpiNUNiYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhPCCqcoOgZpkhVENvTWOvUXMh[W6jbInzbZMhemWuYYTpeoUhfG9iNT3hfoEuSw>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI	MkO3SpVv[3Srb36gZZN{[Xl?	MlO5OVAhdk1?	NWntbHNROiCqcoO=	Mni2TY5kemWjc3WgbY4hPS2jenGt[GNVWC:mQ2TQJJJifGmxIHnuJIh2dWGwIGWzO\|MuVUGJSTDj[YxteyCjdDC1NEBvVSCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KDVvYYrhMYREKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JGxENU2VL13TJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKDVvYYrhMYRE	M{WzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO\|I3ODxxYU6=
U373-MAGI	M1vC[GZ2dmO2aX;uJIF{e2G7	MV:yNFAhdk1?	NIfZSG8zKGi{cx?=	Ml3PTY5kemWjc3WgbY4hPS2jenGt[GNVWC:mQ2TQJJJifGmxIHnuJIh2dWGwIGWzO\|MuVUGJSTDj[YxteyCjdDCyNFAhdk1icILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSB3LXH6ZU1lSyCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KGi{czDifUBNSy2PUz;NV{BidmGueYPpd{Bz\WyjdHn2[UB1dyB3LXH6ZU1lSw>?	MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI	M2rk[2Z2dmO2aX;uJIF{e2G7	NEjEN5MzODBibl2=	MWqyJIhzew>?	MmTvVoVlfWO2aX;uJIlvKGSUR2WtWHAhdGW4ZXygbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy\|IHH0JFIxOCCwTTDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IEWtZZpiNUNiYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhPCCqcoOgZpkhVENvTWOvUXMh[W6jbInzbZM>	NEDXOZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|I3OCd-MkexNVczPjB:L3G+
U373-MAGI	NIDqV\|NHfW6ldHnvckBie3OjeR?=	MnfpNlAxKG6P	MYKyJIhzew>?	MX;S[YR2[3Srb36gbY4hPS2jenGt[GNVWCCuZY\lcEBqdiCqdX3hckBWOzd\|LV3BS2kh[2WubIOgZZQhOjByIH7NJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgOU1igmFvQzDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB2IHjyd{BjgSCOQz3NV{9OWyCjbnHsfZNqew>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI	MYLGeY5kfGmxbjDhd5NigQ>?	M13tVFIxOCCwTR?=	MoDyNkBpenN?	NY\ZZpZQWmWmdXP0bY9vKGmwIHTDWHAhdGW4ZXygbY4hcHWvYX6gWVM4Oy2PQVfJJINmdGy\|IHH0JFIxOCCwTTDwdoVqdmO3YnH0[YQh\m:{IEKgbJJ{KG[xbHzve4VlKGK7IEWtZZpiNWSFIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDRiaILzJIJ6KEyFLV3TM21UKGGwYXz5d4l{KHKnbHH0bZZmKHSxIEWtZZpiNWSF	MlLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI	NG\acVZHfW6ldHnvckBie3OjeR?=	NV\3XlJtPTBibl2=	NWDIeGU2OiCqcoO=	MnnFVoVlfWO2aX;uJIlvKGSFVGCgcIV3\WxiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG2IEWwJI5OKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhPS2jenGt[GMh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOEBpenNiYomgUGMuVVNxTWOgZY5idHm\|aYOgdoVt[XSrdnWgeI8hPS2jenGt[GM>	NFzNU289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|I3OCd-MkexNVczPjB:L3G+
TC32	MUXxTHRUKGG\|c3H5			NFS2O4ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	M4TldlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	M1n1c5FJXFNiYYPzZZk>			NFHWR2lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	NXXSNVdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	NXrONol6eUiWUzDhd5NigQ>?			NXPiV2hFeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	NX;xSGZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	Mne0dWhVWyCjc4PhfS=>			NYHJT49weUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	MonEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MmjDdWhVWyCjc4PhfS=>			NVzUWnRkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	M{jnXZFJXFNiYYPzZZk>			NUK2dZRHeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	M2XpU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NHHkcm9yUFSVIHHzd4F6			Mn\PdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M1HpSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NEPz[\|lyUFSVIHHzd4F6			MnridWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NXvTOVVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	MkDidWhVWyCjc4PhfS=>			NUnY[nhXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NW\aZZVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NWnTRmxWeUiWUzDhd5NigQ>?			MoG1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	NXSxUGlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MmPhdWhVWyCjc4PhfS=>			NWrPVmVXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	NITZ[oo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NF7N[ItyUFSVIHHzd4F6			MoS2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	MnvDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NYrkcFdqeUiWUzDhd5NigQ>?			M1rydJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	NHnWVFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NFXhWINyUFSVIHHzd4F6			MXfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=>	NH\HWZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	M{\SfZFJXFNiYYPzZZk>			MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTTk1ISk1{IHPlcIx{	NIS1e2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MWDxTHRUKGG\|c3H5			NXzHeI02eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	MXjxTHRUKGG\|c3H5			MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	NInlTZhyUFSVIHHzd4F6			MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	MnzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	MoDpdWhVWyCjc4PhfS=>			MknBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	Mk\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NXnKfmN6eUiWUzDhd5NigQ>?			NET3SnFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	M1WyXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	MUXxTHRUKGG\|c3H5			NHvwVpVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NFS5dHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	Mnv4dWhVWyCjc4PhfS=>			MoXhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NYjqbY5jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	MlzrdWhVWyCjc4PhfS=>			Mn33dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	M{ns[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Granta	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		NF33RoQ4OiCqcoO=	NGjUbVFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBIemGwdHGgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCxO:69VQ>?	MoqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzN{[1N\|UoRjNyMUe2OVM2RC:jPh?=
HL60	NVvZfmt2S3m2b4TvfIlkcXS7IHHzd4F6		MmHHO\|IhcHK\|	MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xPM7:TR?=	M3LKdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUe2OVM2Lz5\|MEG3OlU{PTxxYU6=
CCRF-CEM	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=		NHX4V3g4OiCqcoO=	M3\JUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNEWkZvQ1XNJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD6wOFTPxE1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF5NkWzOUc,OzBzN{[1N\|U9N2F-
RL	MmXiR5l1d3SxeHnjbZR6KGG\|c3H5		MonjO\|IhcHK\|	NYPmdmY1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWkxiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjN6zszN	NIPUNHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEG3OlU{PSd-M{CxO\|Y2OzV:L3G+

... Click to View More Cell Line Experimental Data

In vivo

Clofarabine administered intraperitoneally has significant activity against a wide variety of human tumour xenografts implanted subcutaneously in athymic nude or severe combined immune deficiency mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	60 mg/mL (197.57 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300 +1% Tween 80+ddH2O For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Clofarabine SDF

Molecular Weight	303.68
Formula	C₁₀H₁₁ClFN₅O₃
CAS No.	123318-82-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Clolar
Smiles	C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03609814	Active not recruiting	--	Hematologic Malignancies\|Nonmalignant Diseases\|Immunodeficiencies\|Hemoglobinopathies\|Genetic Inborn Errors of Metabolism\|Fanconi''s Anemia\|Thalassemia\|Sickle Cell Disease	University of California San Francisco	February 2016	--
NCT02425904	Active not recruiting	Drug: Clofarabine	Langerhans Cell Histiocytosis	Dana-Farber Cancer Institute\|Sanofi\|St. Baldrick''s Foundation\|Cookies for Kids'' Cancer\|North American Consortium for Histiocytosis	May 2015	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
Cisplatin (NSC 119875)

Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine (LY-188011) HCl

Gemcitabine (LY-188011, NSC 613327) HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Oxaliplatin (NSC 266046)

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Bleomycin (NSC125066) sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine (LY-188011)

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Carboplatin (NSC 241240)

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Features:A DNA synthesis inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Clofarabine